Dimerix Limited announced top-line results from a recent pharmacokinetic (PK) study of an extended release tablet formulation for their DMX-200 program targeting Chronic Kidney Disease (CKD). The study found a newly formulated extended release tablet of DMX-200 taken twice daily (against three times daily for the previous formulation) increases the duration of release of DMX-200 in the human body. The extended release formulation provides a clear benefit by extending the half-life of propagermanium in patients, and will allow a reduced number of daily doses in further studies. The new tablet formulation was manufactured in a Good Manufacturing Practice (GMP) in-line with FDA guidelines, enabling the tablet to be reproduced and used for future studies including the upcoming Phase 2b trial. On the back of these results Dimerix is in the process of patenting the extended release formulation, strengthening the groups patent portfolio around the DMX-200 program which already includes the use of CCR2 antagonists in conjunction with, or sequential to, administration of angiotensin receptor blockers (ARB's), inclusive of treatment in CKD. These patents are granted in the USA, Australian and Japan, with applications pending in a number of major pharmaceutical markets.